Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Chlamydia Psittaci, Stra

Verify with FDA CVM →

25 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
25
Total Reports
1
Deaths Reported
400.0%
Death Rate

Active Ingredients

Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Chlamydia Psittaci, Stra

Administration Routes

Subcutaneous

Species Affected

Cat 25

Most Affected Breeds

Domestic Shorthair 17
Bengal 2
Domestic Mediumhair 2
Domestic Longhair 2
Maine Coon 1
Cat (unknown) 1

Most Reported Reactions

Fever 19
Lethargy (see also Central nervous system depression in Neurological) 14
Intentional misuse 12
Anorexia 7
Not eating 6
Weight loss 5
Vomiting 5
Anaemia NOS 4
Elevated globulins 4
Lameness 4
Not himself/herself 4
Not drinking 3

Outcome Breakdown

Recovered/Normal
12 (48.0%)
Ongoing
9 (36.0%)
Outcome Unknown
3 (12.0%)
Died
1 (4.0%)

Data Summary

Metric Value
Total adverse event reports 25
Reports involving death 1
Case-fatality rate (reported events) 400.0%
Distinct species in reports 1
Distinct breeds in reports 6
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Chlamydia Psittaci, Stra Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 25 adverse event reports referencing Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Chlamydia Psittaci, Stra, including 1 reports in which the animal died — a 400.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Chlamydia Psittaci, Stra. Reported administration route is Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Chlamydia Psittaci, Stra reports are Cat (25 reports), with Cat accounting for the largest share. Within those species, Domestic Shorthair (17), Bengal (2), Domestic Mediumhair (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Chlamydia Psittaci, Stra are Fever (19), Lethargy (see also Central nervous system depression in Neurological) (14), Intentional misuse (12), Anorexia (7). Of the 25 reports with a coded outcome, Recovered/Normal is the leading category at 48.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Chlamydia Psittaci, Stra.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial